REFERENCES
- Stanger O, Herrmann W, Pietrzik K, Fowler B, Geisel J, Dierkes J, et al. DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations. Clin Chem Lab Med. 2003; 41(11)1392–1403, [PUBMED], [INFOTRIEVE], [CSA]
- Loewenstein A, Winder A, Goldstein M, Lazar M, Eldor A. Bilateral retinal vein occlusion associated with 5,10-methylentetrahydrofolate reductase mutation. Am J Ophthalmol. 1997; 124(6)840–841, [PUBMED], [INFOTRIEVE], [CSA]
- Hermann W. Where are we standing in homocysteine research?. Clin Chem Lab Med. 2003; 41(11)1389–1391, [CROSSREF], [CSA]
- Cahill M, Karabatzaki M, Meleady R, Refsum H, Ueland P, Shields D, et al. Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000; 84(2)154–157, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Vine A. Hyperhomocysteinemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol. 2000; 129(5)640–644, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Abu El-Asrar A M, Abdel Gader A G, Al-Amro S A, Al-Attas O S. Hyperhomocysteinemia and retinal vascular occlusive disease. Eur J Ophthalmol. 2002; 12(6)495–500, [PUBMED], [INFOTRIEVE], [CSA]
- Marcucci R, Bertini L, Giusti B, Brunelli T, Fedi S, Cellai A P, et al. Thrombophilic risk factors in patients with central retinal vein occlusion. Thromb Haemost 2001; 86(3)772–776, [PUBMED], [INFOTRIEVE], [CSA]
- Martin S, Rauz S, Marr J, Martin N, Jones A, Dodson P. Plasma total homocysteine and retinal vascular disease. Eye. 2000; 14(4)590–593, [PUBMED], [INFOTRIEVE], [CSA]
- Pianka P, Almog Y, Man O, Goldstein M, Sela B, Loewenstein A. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmol. 2000; 107: 1588–1592, [CSA]
- Boyd S, Owens D, Gin T, Bunce K, Sherafat H, Perry D, et al. Plasma homocysteine, methylene tetrahydrofolate reductase C677T and factor II G20210A polymorphisms, factor VIII, and VWF in central retinal vein occlusion. Br J Ophthalmol. 2001; 85(11)1313–1315, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Larsson J, Hultberg B, Hillarp A. Hyperhomocysteinemia and the MTHFR C677T mutation in central retinal vein occlusion. Acta Ophthalmol Scand 2000; 78(3)340–343, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Glueck C J, Bell H, Vadlamani L, Gupta A, Fontaine R N, Wang P, et al. Heritable thrombophilia and hypofibrinolysis. Possible causes of retinal vein occlusion. Arch Ophthalmol. 1999; 117(1)43–49, [PUBMED], [INFOTRIEVE], [CSA]
- Franken D G, Boers G HJ, Blom H J, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb Vasc Biol. 1994; 14: 465–470, [CSA]
- Cahill M T, Stinnett S S, Fekrat S. Meta-analysis of plasma homocysteine, serum folate, serum vitamin B(12), and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003; 136(6)1136–1150, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Weger M, Stanger O, Deutschmann H, Temmel W, Renner W, Schmut O, et al. Hyperhomocyst(e)inemia and MTHFR C677T genotypes in patients with central retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2002; 240(4)286–290, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]